- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06010628
Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2)
January 31, 2024 updated by: Hui-Sheng Chen, General Hospital of Shenyang Military Region
Intravenous Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2): a Prospective, Randomized, Open Label, Blinded Endpoint, and Multi-center Study
To date, the benefit of intravenous thrombolysis is confined within 4.5 hours of onset for acute ischemic stroke (AIS) patients without advanced neuroimaging selection.
Unpublished pilot EXIT-BT (EXtending the tIme window of Thrombolysis by ButylphThalide up to 6 Hours after onset) suggest the safety, feasibility and potential benefit of intravenous tenecteplase (TNK) in AIS within 4.5 to 6 hours of onset.
The current study aims to investigate the efficacy and safety of TNK for AIS within 4.5 to 6 hours of onset.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
1250
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Shenyang, China, 110016
- Recruiting
- Department of Neurology, General Hospital of Northern Theater Command
-
Contact:
- Hui-Sheng Chen, Ph.D.
- Phone Number: +86 13352452086
- Email: chszh@aliyun.com
-
-
None Selected
-
ShenYang, None Selected, China, 110840
- Recruiting
- Hui-Sheng Chen
-
Contact:
- Yi-Han Wang
- Phone Number: +862428897524
- Email: wangyihan34732512@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥ 18 year
- Acute ischemic stroke confirmed by non-contrast computed tomography;
- The time from last known well to treatment: 4.5 - 6 hours;
- NIHSS ≥ 4 at randomization;
- First stroke onset or past stroke without obvious neurological deficit (mRS≤1);
- Signed informed consent.
Exclusion Criteria:
- Pre-stroke disability (mRS≥2);
- Planned intravenous thrombolysis based on WAKE-UP or EXTEND study criterion;
- Any contraindication to intravenous thrombolysis: Obvious head injury or stroke within 3 months; Subarachnoid or intracranial hemorrhage; History of intracranial hemorrhage; Intracranial tumor, arteriovenous malformation or aneurysm; Intracranial or spinal cord surgery within 3 months; Myocardial infarction within 3 months; Major surgery within 1 month; Gastrointestinal or urinary tract hemorrhage within the previous 30 days; Arterial puncture at a noncompressible site within the previous seven days; Active internal hemorrhage; Coagulation abnormalities: platelet count of <100000/mm3; Aortic arch dissection; Heparin therapy within 24 hours; Infective endocarditis; Oral warfarin is being taken and INR>1.6 or APTT abnormal; Systolic pressure ≥185 mmHg or diastolic pressure ≥110 mmHg; Blood glucose < 50 mg/dl (2.7mmol/L); Neurological deficit after epileptic seizures;
- Pregnancy;
- Allergy to test drugs;
- Comorbidity with other serious diseases;
- Participating in other clinical trials within 3 months;
- Patients not suitable for the study considered by researcher.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Control group
standard stroke care based on national guideline
|
intravenous tenecteplase (0.25 mg/kg, a single bolus over 5 to 10 seconds, a maximum of 25 mg).
|
Experimental: Tenecteplase group
intravenous thrombolysis with tenecteplase
|
intravenous tenecteplase (0.25 mg/kg, a single bolus over 5 to 10 seconds, a maximum of 25 mg).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
proportion of modified Rankin Scale (mRS) 0-1
Time Frame: 90±7 days
|
The minimum and maximum values of mRS are 0 and 6, respectively; higher score mean a worse outcome
|
90±7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
proportion of modified Rankin Scale (mRS) 0-2
Time Frame: 90±7 days
|
The minimum and maximum values of mRS are 0 and 6, respectively; higher score mean a worse outcome
|
90±7 days
|
ordinal distribution of modified Rankin Scale (mRS)
Time Frame: 90±7 days
|
The minimum and maximum values of mRS are 0 and 6, respectively; higher score mean a worse outcome
|
90±7 days
|
change in National Institute of Health stroke scale (NIHSS) score
Time Frame: 24 (-6/+12) hours
|
the minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome.
|
24 (-6/+12) hours
|
change in National Institute of Health stroke scale (NIHSS) score
Time Frame: 10±2 days
|
the minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome.
|
10±2 days
|
occurrence of early neurological improvement (ENI)
Time Frame: 24 (-6/+12) hours
|
ENI is defined as more than 4-point decrease in National Institute of Health stroke scale score
|
24 (-6/+12) hours
|
new stroke or other vascular event(s)
Time Frame: 90±7 days
|
90±7 days
|
|
all-cause mortality
Time Frame: 90±7 days
|
90±7 days
|
|
intracranial hemorrhage
Time Frame: 24 (-6/+12) hours
|
any evidence of bleeding on the head CT scan, classified by the Heidelberg Bleeding Classification
|
24 (-6/+12) hours
|
major systemic bleeding event
Time Frame: 24 (-6/+12) hours
|
24 (-6/+12) hours
|
|
any bleeding event
Time Frame: 24 (-6/+12) hours
|
24 (-6/+12) hours
|
|
symptomatic intracranial hemorrhage (sICH)
Time Frame: 24 (-6/+12) hours
|
sICH is defined as parenchymal hematoma type 1 or 2 (PH1 or PH2), remote intraparenchymal hematoma (RIH), subarachnoid hemorrhage, or intraventricular hemorrhage on head CT/MRI scan causally associated with clinically significant neurological deterioration (NIHSS score ≥4 point increase) in the opinion of the clinical investigator or independent safety monitor.
|
24 (-6/+12) hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2024
Primary Completion (Estimated)
March 15, 2025
Study Completion (Estimated)
March 15, 2025
Study Registration Dates
First Submitted
August 20, 2023
First Submitted That Met QC Criteria
August 20, 2023
First Posted (Actual)
August 24, 2023
Study Record Updates
Last Update Posted (Actual)
February 2, 2024
Last Update Submitted That Met QC Criteria
January 31, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Y (2023) 144
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke, Ischemic
-
Nordsjaellands HospitalRigshospitalet, Denmark; Metropolitan University CollegeCompletedTransient Ischemic Attack | Stroke, Ischemic | Stroke HemorrhagicDenmark
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
Umbria Bioengineering TechnologiesRecruitingStroke, Ischemic | Stroke HemorrhagicItaly
-
University Hospital, BrestCompletedStroke, Ischemic | Stroke HemorrhagicFrance
-
BayerRecruitingAcute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic AttackUnited States, Switzerland, Belgium, Australia, Sweden, Canada, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, China, Greece, Japan, Turkey, Netherlands, Romania, United Kingdom, Portugal, Hungary, Italy, Brazil, France, S... and more
-
Sheffield Teaching Hospitals NHS Foundation TrustUnknownFatigue | Stroke, Ischemic | Stroke HemorrhagicUnited Kingdom
-
University of AlbertaCompletedTransient Ischemic Attack | Minor Ischemic StrokeCanada
-
Stephanie HarrisonActive, not recruitingTransient Ischemic Attack | Stroke, IschemicUnited Kingdom
Clinical Trials on Tenecteplase
-
Kaiser PermanenteGenentech, Inc.TerminatedPleural EffusionUnited States
-
Huashan HospitalShanghai 10th People's Hospital; Shanghai East Hospital; The Second Affiliated... and other collaboratorsCompleted
-
Boehringer IngelheimTerminatedHeart ArrestGermany, Belgium, Sweden, France, Austria, Italy, Norway, Spain, Switzerland
-
Genentech, Inc.CompletedDysfunctional Central Venous Access Catheters
-
The George InstituteUniversity of Calgary; Berry ConsultantsNot yet recruiting
-
University Of PerugiaTerminated
-
Genentech, Inc.CompletedDysfunctional Hemodialysis Catheters
-
Genentech, Inc.CompletedDysfunctional Central Venous Access Catheters
-
General Hospital of Shenyang Military RegionCompleted
-
Second Affiliated Hospital of Guangxi Medical UniversityCSPC Pharmaceutical Group LimitedNot yet recruiting